Beam Therapeutics (BEAM) reported a Q3 net loss Tuesday of $1.17 per share, narrowing from a loss of $1.22 a year earlier.
Analysts polled by Capital IQ expected a loss of $1.15.
License and collaboration revenue for the quarter ended Sept. 30 was $14.3 million, down from $17.2 million a year earlier.
Analysts surveyed by Capital IQ expected $14.1 million.
The company said it had $925.8 million in cash, cash equivalents and marketable securities as of Sept. 30 to fund its operations into 2027.
Shares of the company were down over 10% in recent premarket activity.
Price: 21.60, Change: -2.76, Percent Change: -11.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments